Faculty profile

Marco Solmi

Back to faculty

Associate ProfessorPsychiatryUniversity of Ottawa

Marco Solmi

Associate Professor

Psychiatry

Faculty of Medicine

University of Ottawa

Ottawa, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
338 publications in the last five years, latest in 2026.
Senior (last) author on 72 recent papers, a sign of leading a research group.
Principal investigator on 5 research grants (5 CIHR), most recently in 2025.
Supervised 1 trainee who won CIHR awards, most recently in 2024.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

348

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

University Profile Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Ottawa profile.

Bipolar Disorder Adults Candesartan Depressive Symptoms Randomized Clinical Trial Renin-Angiotensin System Living Systematic Review Mdma

Latest papers

UNIversity students' LIFEstyle behaviours and Mental health cohort (UNILIFE-M): study protocol of a multicentre, prospective cohort study.
BMJ open · 2026
Interventions for negative symptoms in schizophrenia: efficacy and clinical interpretability in a meta-analysis of 451 randomized controlled trials.
Molecular psychiatry · 2026
Probiotics in reducing negative symptoms of schizophrenia: A systematic review and meta-analysis.
Progress in neuro-psychopharmacology & biological psychiatry · 2026 · senior author

All 348 publications

Latest funding

Advancing the CCBHC by Leveraging Existing Longitudinal Cohorts and Investigating Psilocybin as a Novel Treatment for Cannabis Use Disorder
CIHR · 2026 · Co-investigator
$2,400,000
Expanding Research on High-Potency Cannabis Use in Psychosis: Longitudinal Neurobiological Investigations and Evaluation of a Novel Virtual Reality Intervention for Cannabis Use Disorder
CIHR · 2026 · Co-investigator
$2,350,000
Metformin for treatment-resistant bipolar depression (TRBD) with co-morbid insulin resistance (IR): A double-blind randomized control trial
CIHR · 2025 · Co-investigator
$1,510,875

All 14 grants and awards

From the 150 most recent of 348 publications.

UNIversity students' LIFEstyle behaviours and Mental health cohort (UNILIFE-M): study protocol of a multicentre, prospective cohort study.

Schuch FB, Waclawoscky A, Tornquist D, Oyeyemi AL, Sadarangani KP, Takano K, Teychenne M, Balanzá-Martínez V, O'Neil A, Romain AJ, McGrath A, Anselmi A, Andrade-Lima A, Zanetti ACG, Trompetero-González AC, Heissel A, Silva AFD, Benavides ACZ, Ruusunen A, Cristi-Montero C, Weise C, Pires DA, Silva DRP, Pelupessy DC, Dos Santos EB, Caputo EL, Critselis E, Dragioti E, Matthews E, de Jesus-Moraleida FR, Gomes FA, Bachtiar F, Silva-Junior FLE, Sallem H, Moura H, Womboh I, Grabovac I, Meyer JD, Ramos-Diaz J, Bueno-Antequera J, de Oliveira J, Deenik J, Soto-Sánchez J, van der Kaap-Deeder J, Leo Ng J, López-Gil JF, Firth J, Teixeira JA, Nikonov JR, Hoyer J, Carneiro L, Zou L, Farrer LM, Woud ML, Solmi M, Guimarães MEA, Gerber M, Reichert M, Jenkins M, Savage MJ, Hoffmann MS, Hutchesson M, Gonzalez Henao ME, Chong MJM, Morina N, Galvão-Coelho NL, Heinrichs N, Montoya-Hurtado OL, Ewah PA, Salameh P, De Boni R, Cheung RYM, Monteiro-Junior RS, White RL, Haider S, Baldew SS, Gow S, Rosenbaum S, Hallit S, Piccinin SG, Heinzel S, Torres S, Rashid T, Matias TS, Rohe T, Meireles T, Reyes-Ferrada W, Zhang Y, Frei AK, Deslandes A, Wolf S

BMJ open2026

DOI: 10.1136/bmjopen-2024-085006 PMID: 41526014

Interventions for negative symptoms in schizophrenia: efficacy and clinical interpretability in a meta-analysis of 451 randomized controlled trials.

Damiani S, Stefanelli R, Fortea L, D'Imperio A, Calò M, Casarini F, Crippa A, Esposito CM, Leggi R, Orlandi M, Patron S, Peviani A, Piccolo A, Provenzani U, Santilli F, Spallarossa C, Papanastasiou E, Cella M, Patel R, Solmi M, Galderisi S, Leucht S, Stahl D, Radua J, Fusar-Poli P

Molecular psychiatry2026

DOI: 10.1038/s41380-026-03543-1 PMID: 41872518

Probiotics in reducing negative symptoms of schizophrenia: A systematic review and meta-analysis.

Ramirez J, Maresca T, Lopez P, Corral R, Corrales A, Cabrera A, Romero-Ferreiro V, Solmi M

Progress in neuro-psychopharmacology & biological psychiatry2026Senior author

DOI: 10.1016/j.pnpbp.2026.111820 PMID: 42392560

Relative risk and risk factors of all-cause, natural-cause and external-cause mortality after psychiatric hospitalisation: a population-based electronic health-record study in Hong Kong.

Chan JKN, Lui SSY, Choo LLT, Chu NWT, Chung AWY, Wong CSM, So HC, Sham PC, Solmi M, Correll CU, Chang WC

EClinicalMedicine2026

DOI: 10.1016/j.eclinm.2026.104076 PMID: 42518937

Aerobic Exercise and Subthreshold Depressive Symptoms in Adolescents: Secondary Analysis of a Randomized Clinical Trial.

Yan X, Shao R, Jin J, Lu W, Jiang Z, Zhang G, Zhang Q, Li X, Tian X, Stubbs B, Vancampfort D, Solmi M, Fornaro M, Carvalho AF, Yau SS, Cong F, So KF, Lin K

JAMA network open2026

DOI: 10.1001/jamanetworkopen.2026.21568 PMID: 42406403

Evidence-based atlas of risk and protective factors for psychotic disorders: an umbrella review to inform personalized prognosis and prevention.

Aymerich C, De Prisco M, Melillo A, Pedruzo B, Catalan A, Oliver D, Diederen K, MacCabe J, Twumasi R, Uher R, Davies C, Alameda L, Arango C, Vieta E, Correll CU, Lund C, Nordentoft M, Pollak TA, Yon DK, Cortese S, Fusar-Poli L, Damiani S, Jauhar S, Grassi L, Monteleone AM, Capra M, Stirpe I, de Girolamo G, Salazar de Pablo G, Cervenka S, Solmi M, Tonna M, Murray R, Howes O, Radua J, Fusar-Poli P

World psychiatry : official journal of the World Psychiatric Association (WPA)2026

DOI: 10.1002/wps.70093 PMID: 42742591

Translating Pharmacokinetics and Pharmacodynamics into Clinical Decision-Making: A Practical Guide to the Use of Risperidone ISM® in Schizophrenia.

Solmi M, Corbeil O, Miguelez M, Procyshyn RM, Blier P, Barakat M, Correll CU

Journal of clinical medicine2026First author

DOI: 10.3390/jcm15166393 PMID: 42652797

Evidence based interventions for bipolar disorder across phases and age groups: living umbrella review, evaluation, analysis, and communication hub (U-REACH) project.

De Prisco M, Oliva V, Miola A, Fornaro M, Dragioti E, Croatto G, Carvalho AF, Berk M, Nikolitch K, Saraf G, Yatham LN, Keramatian K, Shorr R, Frye MA, Singh B, Krinitski D, Højlund M, Serretti A, Fanelli G, Gomes FA, Hansen AS, Nielsen RE, Fusar-Poli P, Paribello P, Manchia M, Bahji A, Vazquez G, Siafis S, Leucht S, Yildiz A, Delorme R, Schaffer A, Stubbs B, Rubaiyat R, Vieta E, Correll CU, Moher D, Cortese S, Fiedorowicz JG, Radua J, Gosling CJ, Solmi M

BMJ (Clinical research ed.)2026Senior author

DOI: 10.1136/bmj-2026-100216 PMID: 42580772

Changes over time in hallucinogen-related emergency department visits in Ontario, Canada.

Myran DT, MacDonald-Spracklin R, Levesque AR, Pugliese M, Fiedorowicz JG, McDonald AJ, Rosenblat JD, Colman I, Zein J, Solmi M

Addiction (Abingdon, England)2026Senior author

DOI: 10.1111/add.70363 PMID: 41821125

Mortality following cancer diagnosis among people with non-affective psychoses: mediation by stage at diagnosis and time to treatment initiation.

Wootten JC, Richard L, Karp I, Blanchette PS, Solmi M, Anderson KK

Social psychiatry and psychiatric epidemiology2026

DOI: 10.1007/s00127-026-03063-x PMID: 41784654

Profile data last refreshed on September 25, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Marco Solmi

Research

Latest papers

Latest funding

UNIversity students' LIFEstyle behaviours and Mental health cohort (UNILIFE-M): study protocol of a multicentre, prospective cohort study.

Interventions for negative symptoms in schizophrenia: efficacy and clinical interpretability in a meta-analysis of 451 randomized controlled trials.

Probiotics in reducing negative symptoms of schizophrenia: A systematic review and meta-analysis.

Relative risk and risk factors of all-cause, natural-cause and external-cause mortality after psychiatric hospitalisation: a population-based electronic health-record study in Hong Kong.

Aerobic Exercise and Subthreshold Depressive Symptoms in Adolescents: Secondary Analysis of a Randomized Clinical Trial.

Evidence-based atlas of risk and protective factors for psychotic disorders: an umbrella review to inform personalized prognosis and prevention.

Translating Pharmacokinetics and Pharmacodynamics into Clinical Decision-Making: A Practical Guide to the Use of Risperidone ISM&#xae; in Schizophrenia.

Evidence based interventions for bipolar disorder across phases and age groups: living umbrella review, evaluation, analysis, and communication hub (U-REACH) project.

Changes over time in hallucinogen-related emergency department visits in Ontario, Canada.

Mortality following cancer diagnosis among people with non-affective psychoses: mediation by stage at diagnosis and time to treatment initiation.

Frequent collaborators

Lin Yang

Jess Fiedorowicz

Peter Tanuseputro

Gayatri Saraf

David Moher

Ian Colman

Marie-France Demers

Colleen Webber

Simon Hatcher

Ayub Akbari

Ayal Schaffer

Mark Kaluzienski

Benedikt Fischer

Yaron Finkelstein

Katerina Nikolitch

Margaret Hahn

David Castle

Rudolf Uher

Andrew Olagunju

Thomas Hastings

Lauri Tuominen

Synthia Guimond

Kamyar Keramatian

Oghenowede Eyawo

Sara Tremblay

Areti-Angeliki Veroniki

Igor Karp

Pamela Kryskow

Zacharie Saint-Georges

Translating Pharmacokinetics and Pharmacodynamics into Clinical Decision-Making: A Practical Guide to the Use of Risperidone ISM® in Schizophrenia.